SAFC and Novozymes Biopharma have announced a 10-year extension of their joint agreement based on the LONGRIGF-I (LONGR3) growth factor for industrial cell culture applications.
Under the agreement, SAFC will retain exclusive marketing and distribution rights for Novozymes Biopharma's LONGRIGF-I (LONGR3) growth factor, which is manufactured specifically for customers in the cell culture market, to enable them to reduce operational and regulatory complexity and minimise manufacturing risk.
LONGR3 is expected to enhance the productivity and performance of industrial cell culture processes, replacing insulin in cell culture, specifically binding to type I IGF receptors to stimulate cell growth and support survival in serum-free media.
The growth factor offers customers a range of benefits, from ease-of-use and flexibility to reduced complexity of manufacturing processes and superior performance.
LONGR3 is said to provide increased cell density, higher viability and extended culture duration, without comprising on safety or regulatory compliance.
